Cyclacel Pharmaceuticals Files 8-K on Financials
Ticker: BGMSP · Form: 8-K · Filed: May 14, 2024 · CIK: 1130166
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cyclacel dropped an 8-K on May 14th about their financials. Nothing earth-shattering in the snippet, but check it for the deets.
AI Summary
On May 14, 2024, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Cyclacel Pharmaceuticals' financial status and operational results, which is crucial information for investors and stakeholders to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial condition and results of operations, with no immediate indication of significant negative events.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- May 14, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Berkeley Heights, NJ (location) — Principal Executive Office Address
FAQ
What is the primary purpose of this 8-K filing by Cyclacel Pharmaceuticals?
The primary purpose of this 8-K filing is to report on Cyclacel Pharmaceuticals' results of operations and financial condition, along with financial statements and exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on May 14, 2024.
In which state is Cyclacel Pharmaceuticals incorporated?
Cyclacel Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive address of Cyclacel Pharmaceuticals?
The principal executive address of Cyclacel Pharmaceuticals is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Does the provided excerpt detail specific financial results or significant events?
No, the provided excerpt of the 8-K filing does not detail specific financial results or significant events.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-05-14 16:05:49
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
Filing Documents
- tm2414455d1_8k.htm (8-K) — 28KB
- tm2414455d1_ex99-1.htm (EX-99.1) — 64KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 3KB
- 0001104659-24-061146.txt ( ) — 324KB
- cycc-20240514.xsd (EX-101.SCH) — 3KB
- cycc-20240514_def.xml (EX-101.DEF) — 26KB
- cycc-20240514_lab.xml (EX-101.LAB) — 36KB
- cycc-20240514_pre.xml (EX-101.PRE) — 25KB
- tm2414455d1_8k_htm.xml (XML) — 5KB
02 Results
Item 2.02 Results of Operations and Financial Condition. The information set forth under this "Item 2.02. Results of Operations and Financial Condition," including the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Attached as Exhibit 99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the " Company "), dated May 14, 2024, announcing certain financial results for the first quarter ended March 31, 2024. The Company will conduct a conference call to review its financial results on May 14, 2024, at 4:30 p.m., Eastern Time.
01. Financial
Item 9.01. Financial (d) Exhibits. Exhibit No. Exhibit 99.1 Press release announcing financial results for the first quarter ended March 31, 2024, dated May 14, 2024. 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: May 14, 2024